On 15 September 2026 the FDA approved Garzulys (insulin aspart-fsan) from Emerge Bioscience under a biologics licence application. The FDA notice confirms the approval and the active substance; it does not, in the record available, state whether the product is designated biosimilar or interchangeable.
For prescribers this is a supply and cost question rather than a clinical one: the molecule is insulin aspart, a rapid-acting analogue. Whether it is available in India, or has any CDSCO approval, is not known from this notice.
- The approval is from the FDA in the USA; CDSCO status is unknown.
- The active substance is insulin aspart, a rapid-acting analogue.
- When any insulin product is switched, check the device, the strength and the patient's technique with the new pen.
- Advise closer glucose checks for the first weeks after any switch.
Why it matters
More insulin aspart products widen supply and may lower price, but each switch is a moment where dosing errors happen.
Don't overread it
A licence approval is not evidence that it is interchangeable with existing aspart products without prescriber involvement.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free